173 related articles for article (PubMed ID: 8302362)
1. Comparative efficacy of amphotericin B, clotrimazole and itraconazole against Aspergillus spp. An in vitro study.
Hahn YH; Ahearn DG; Wilson LA
Mycopathologia; 1993 Sep; 123(3):135-40. PubMed ID: 8302362
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species.
Denning DW; Hanson LH; Stevens DA
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):693-7. PubMed ID: 2171940
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species.
Gao L; Ding X; Liu Z; Wu Q; Zeng T; Sun Y
Antimicrob Agents Chemother; 2016 Jun; 60(6):3813-6. PubMed ID: 26976874
[TBL] [Abstract][Full Text] [Related]
5. Does hydrocortisone modify the in vitro susceptibility of Aspergillus fumigatus to itraconazole and amphotericin B?
Ramondenc I; Pinel C; Ambroise-Thomas P; Grillot R
Med Mycol; 1998 Apr; 36(2):69-73. PubMed ID: 9776816
[TBL] [Abstract][Full Text] [Related]
6. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
J Antimicrob Chemother; 1999 Oct; 44(4):553-5. PubMed ID: 10588320
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp.
Moore CB; Law D; Denning DW
J Antimicrob Chemother; 1993 Dec; 32(6):831-6. PubMed ID: 8144422
[TBL] [Abstract][Full Text] [Related]
8. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo.
Mosquera J; Warn PA; Morrissey J; Moore CB; Gil-Lamaignere C; Denning DW
Antimicrob Agents Chemother; 2001 May; 45(5):1456-62. PubMed ID: 11302810
[TBL] [Abstract][Full Text] [Related]
11. Effect of methotrexate on the germination and growth of Aspergillus fumigatus and Aspergillus flavus strains.
Warnock DW; Oliver DA; Cheung MM; Zurick NJ
J Antimicrob Chemother; 1992 Apr; 29(4):375-81. PubMed ID: 1607326
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
14. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.
Chandrasekar PH; Cutright JL; Manavathu EK
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):211-4. PubMed ID: 11777662
[TBL] [Abstract][Full Text] [Related]
15. Synergism of CAY-1 with amphotericin B and itraconazole.
De Lucca AJ; Bland JM; Boue S; Vigo CB; Cleveland TE; Walsh TJ
Chemotherapy; 2006; 52(6):285-7. PubMed ID: 17008779
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.
Manavathu EK; Cutright J; Chandrasekar PH
J Clin Microbiol; 1999 Mar; 37(3):858-61. PubMed ID: 9986876
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
19. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
20. Comparison between Aspergillus fumigatus conidia and hyphae susceptibilities to amphotericin B, itraconazole, and voriconazole by use of the mold rapid susceptibility assay.
Wetter TJ; Hazen KC; Cutler JE
Med Mycol; 2005 Sep; 43(6):525-32. PubMed ID: 16323310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
